Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Meeting Abstract

    Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC)
    Meeting Abstract

    Mackay, H.; Tinker, A.; Nelson, B.; Zamarin, D.; Odunsi, K.; Lheureux, S.; Ellard, S.; Smrke, A.; Gaudreau, P. O.; Faulkner, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    Hays, J. L.; Friedman, C. F.; Lakhani, N.; Anderson, C. K.; Buscema, J.; Duska, L. R.; Hamilton, E. P.; Taylor, S. E.; Carrington, C.; Burger, R. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
    Meeting Abstract

    Moore, K. N.; Bouberhan, S.; Hamilton, E. P.; Liu, J. F.; O'Cearbhaill, R. E.; O'Malley, D. M.; Papadamitriou, K.; Schröder, D.; Van N., Els; Yoo, S. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Sridhar, S. S.; Chen, R. C.; Chan, T. A.; Wen, Y.; Grivas, P.; Tan, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Zebic, D. S.; Tran, B.; Martin, A. J.; Pashankar, F. D.; Mazhar, D.; Huddart, R. A.; Wheater, M.; Walpole, E. T.; Dunwoodie, E.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Chism, D. D.; Saraiya, B.; Dorff, T. B.; Curti, B. D.; Posadas, E. M.; St. Paul, C.; Mukhopadhyay, S.; Desai, L.; Lauterbach, H.; Nassirpour, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC)
    Meeting Abstract

    Coleman, J.; Margulis, V.; Scherz, A. J.; Krasnopolskaya, I.; Alpert, G.; Jobert, V.; Preise, D.; Shore, N. D.; UCM301 Investigators
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma
    Meeting Abstract

    Klempner, S. J.; Shitara, K.; Sison, A.; Scott, J.; Wishengrad, D.; Ronayne, J.; Rhee, J.; Mitra, S.; Nuyten, D. S. A.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save